Mankind Pharma Ltd's Q4FY25 Quarter Results
- 22 May 2025
Result Summary
- Mankind Pharma Ltd reported a 23.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.6%.
- Its expenses for the quarter were down by 30.2% QoQ and up 13.8% YoY.
- The net profit increased 23.9% QoQ and increased 62.3% YoY.
- The earnings per share (EPS) of Mankind Pharma Ltd stood at 11.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2533.23 | 3307.32 | 2100.18 | -23.4% | 20.6% |
Total Expenses | 1964.07 | 2813.43 | 1725.67 | -30.2% | 13.8% |
Profit Before Tax | 569.16 | 493.89 | 374.51 | 15.2% | 52.0% |
Tax | 94.98 | 112.81 | 83.59 | -15.8% | 13.6% |
Profit After Tax | 476.59 | 384.52 | 293.70 | 23.9% | 62.3% |
Earnings Per Share | 11.70 | 9.40 | 7.10 | 24.5% | 64.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Mankind Pharma Ltd is a prominent entity in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations. The company's product portfolio includes prescription medicines, over-the-counter drugs, and other healthcare products. Mankind Pharma has gained a reputation for its focus on delivering affordable and accessible healthcare solutions. As of the latest data available up to October 2023, there are no specific major developments or changes in their product offerings or strategic direction that have been publicly announced. However, Mankind Pharma continues to be a significant player in its sector, catering to a diverse range of healthcare demands both domestically and internationally.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Mankind Pharma Ltd reported a total income of ₹2533.23 crores. This represents a decrease of 23.4% from the previous quarter (Q3FY25), where the total income was ₹3307.32 crores. However, when compared to the same quarter of the previous year (Q4FY24), the total income shows a notable year-over-year increase of 20.6% from ₹2100.18 crores. This indicates variations in the company's revenue performance over different periods, reflecting changes in sales volumes or pricing strategies within the fiscal year.
Profitability
The company's profitability metrics for Q4FY25 indicate a profit before tax of ₹569.16 crores, which is a 15.2% increase compared to Q3FY25, where the profit before tax was ₹493.89 crores. Year-over-year, the profit before tax rose by 52.0% from ₹374.51 crores in Q4FY24. After accounting for tax expenses, Mankind Pharma's profit after tax in Q4FY25 was ₹476.59 crores, marking a 23.9% quarter-over-quarter increase from ₹384.52 crores in Q3FY25 and a significant 62.3% year-over-year increase from ₹293.70 crores in Q4FY24. These figures reflect changes in the company's profitability over time, which may be influenced by a combination of revenue changes and cost management.
Operating Metrics
The total expenses for Mankind Pharma in Q4FY25 were reported at ₹1964.07 crores, showing a significant decrease of 30.2% compared to the previous quarter's expenses of ₹2813.43 crores. When compared to Q4FY24's expenses of ₹1725.67 crores, there is a 13.8% year-over-year increase. The earnings per share (EPS) for Q4FY25 stood at ₹11.70, which is 24.5% higher than the ₹9.40 reported in the previous quarter and 64.8% higher than the ₹7.10 reported in the same quarter of the previous year. These operating metrics highlight fluctuations in the company's cost management and shareholder value over the given periods.